The Becton, Dickinson and Company (NYSE:BDX) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan. In July, Embecta, a ...
Embecta said Tuesday that it will cancel its insulin patch pump program just months after receiving clearance from the Food and Drug Administration for its first product. The Parsippany ...
A London scientist is working on the world’s first oral insulin patch that could save diabetes patients from having to regularly inject the drug. Dr Hend Abdelhakim, an assistant professor at ...
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
Get up to 30% off detailed market research reports-for a limited time only! The insulin patch pumps market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...